Your academic skills will take you 70% of the way. Here's the other 30%.
Updated: Sep 29
The criteria didn't change. What reviewers expect from your answers did.
If you've spent any time in academic research, you already know how to write a grant.
You know how to build a hypothesis, justify your aims, write to a skeptical reviewer, and structure a complex document under deadline pressure. That experience is real and it absolutely transfers.
But if you've recently spun out a startup, or you're staring at your first SBIR score wondering what went wrong, there's something worth knowing: the rules changed when you crossed over, and nobody hands you a memo.
The core review criteria look identical. Significance, innovation, approach, investigator, environment. It’s the same five categories you've always known. But what reviewers are actually looking for inside each one is a fundamentally different conversation in the biotech grants world.
In academia, the central question is: is this good science? Is the hypothesis sound, is the approach rigorous, does this advance the field? In biotech grants, that question has a second half: and will it become something? A brilliant scientific approach with no credible commercialization story will score worse than slightly less elegant science with a clear, believable path to market. That is not a flaw in the system. That is what SBIR is designed to do.
The specific places where this shows up most often: the commercialization plan, which doesn't exist in academic grants and is a fully scored section in SBIR. Preliminary data, which needs to signal real-world viability, not just scientific feasibility. The team section, where business acumen and operational experience matter alongside publication record. And the reviewer lens itself, which is always asking whether this science has a life outside the lab.
None of this is hard to learn. Most researchers who make the transition successfully do it by recognizing that the underlying craft is the same and the audience has different questions. Write like a scientist. Think like a founder. That combination is what wins in this space.
Comments